Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We further show that superactivation of the prosurvival PI3K-AKT signaling pathway limits the efficacy of a PARP single-agent treatment, and that PARP and PI3K inhibitors effectively synergize to suppress tumorigenesis in human prostate cancer cell lines and in a Pten/Trp53-deficient mouse model of advanced prostate cancer.
|
24866151 |
2014 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Both mechanisms are correlated to the Pi3K/Akt/mTOR pathway which is a major tumorigenesis pathway in nearly all phacomatoses.
|
28265819 |
2018 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Functional screening of FGFR4-driven tumorigenesis identifies PI3K/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma.
|
29487419 |
2018 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Activation of the PI3K and epidermal growth factor receptor (EGFR) pathway is able to drive oncogenesis in multiple human cancers, including head and neck squamous cell carcinoma.
|
22065749 |
2011 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The PI3K pathway is considered to play an important role in tumorigenesis.
|
19305151 |
2009 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Furthermore, PI3K/AKT may contribute to the carcinogenesis and development of human meningiomas in combination with HER-2.
|
25998419 |
2015 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
R-Ras2 drives tumorigenesis in a phosphatidylinostiol-3 kinase (PI3K)-dependent and signalling autonomous manner.
|
24826867 |
2014 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
NDRG4 is a novel candidate tumor suppressor and can inhibit PI3K/AKT signal which is related with energy balance and related carcinogenesis.
|
26515606 |
2016 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Some in vitro studies have shown that EGFR and PI3K-Akt pathway play an important role in the carcinogenesis of bile duct carcinoma.
|
27020207 |
2016 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The phosphatidylinositol 3-kinase (PI3K)/PTEN/AKT/mTOR and Ras/Raf/MEK/ERK pathways have been implicated in endometrial tumorigenesis.
|
22146979 |
2012 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Computational analysis indicated that miR-296-3p targeted PTEN, which regulates the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway and PTEN is involved in the carcinogenesis of SCC. miR-296-3p directly regulated PTEN expression in head and neck cancer cells, with PTEN protein levels decreased in 4/19 the SCCs (21.0%), as compared with those in the IPs (76.4%).
|
28693263 |
2017 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The findings indicate that epigenetic inactivation of INPP4B is one of the key mechanisms in activating PI3K/AKT signaling cascade and playing a role in the tumorigenesis of NPC.
|
25126743 |
2014 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We concluded that 3,6-DHF upregulates miR-34a via inhibiting DNMT1 and hypermethylation, whereas downregulates miR-21 by modulating histone modification, and consequently suppresses the PI3K/Akt/mTOR signaling pathway in breast carcinogenesis.
|
25784176 |
2015 |
Carcinogenesis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Our results suggest that GP130-dependent activation of the druggable PI3K/mTORC1 pathway is required for inflammation-associated gastrointestinal tumorigenesis.
|
23321674 |
2013 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Studies using an H-Ras construct to constitutively and preferentially activate the three best-defined downstream targets of Ras, i.e., Raf, RalGDS, and PI3K, showed that mutant Ras mediates resistance through its ability to use multiple pathways for tumorigenesis.
|
19117997 |
2009 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
<b>Background:</b> Phosphatidylinositol 3-kinase (PI3K) pathway activation plays a key role in tumorigenesis and has been associated with poor prognosis and resistance to multiple therapies in various cancers.
|
31741715 |
2019 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
To investigate if analysis of genetic alterations in the main pathways involved in endometrioid type carcinogenesis (PI3K-AKT, Wnt/β-catenin, P53-activation and MSI) improves the current risk assessment based on clinicopathological factors.
|
22609107 |
2012 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The PI3K-AKT-mTOR signaling pathway plays a crucial role in the initiation and progress in tumorigenesis including breast tumorigenesis and regulates critical cellular functions including survival, proliferation, and metabolism.
|
28216025 |
2017 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
LncRNA MEG3 inhibit endometrial carcinoma tumorigenesis and progression through PI3K pathway.
|
29094270 |
2017 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
PI3K pathway activation may drive tumorigenesis in a subset of MCC and screening these tumors for PIK3CA mutations could help identify patients who may respond to treatment with PI3K pathway inhibitors.
|
22261808 |
2012 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Astrocyte-elevated gene-1 (AEG-1) expression is increased in multiple cancers and plays a central role in Ha-ras-mediated oncogenesis through the phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway.
|
19940250 |
2009 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The RAS and PI3K-AKT signaling pathways play an important role in oral carcinogenesis.
|
19628422 |
2009 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The phosphatidylinositol 3-kinase (PI3K)/AKT pathway plays an important role in thyroid tumorigenesis and progression.
|
18831514 |
2008 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Interaction between IGF2-PI3K axis and cancer-associated-fibroblasts promotes anal squamous carcinogenesis.
|
30714617 |
2019 |
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Transcriptome analysis revealed that major transcription factors, such as SRF, HNF4A, ZEB1, and RUNX1, with potential regulatory roles in key pathways, including focal adhesion, the PI3K-Akt signaling pathway, and the MAPK signaling pathway, may play a role in the tumorigenesis of SRCC.
|
29747153 |
2018 |